Literature DB >> 12392769

Open peer commentary regarding Abeta immunization and CNS inflammation by Pasinetti et al.

Pritam Das1, Todd E Golde.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12392769     DOI： 10.1016/s0197-4580(02)00031-3

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN： 0197-4580            Impact factor:   4.673


× No keyword cloud information.
  4 in total

1.  Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model.

Authors:  Yona Levites; Pritam Das; Robert W Price; Marjorie J Rochette; Lisa A Kostura; Eileen M McGowan; Michael P Murphy; Todd E Golde
Journal:  J Clin Invest       Date:  2005-12-08       Impact factor: 14.808

Review 2.  What is the dominant Abeta species in human brain tissue? A review.

Authors:  Gillian C Gregory; Glenda M Halliday
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

Review 3.  Alzheimer disease therapy: can the amyloid cascade be halted?

Authors:  Todd E Golde
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

4.  Interleukin-1 receptor 1 knockout has no effect on amyloid deposition in Tg2576 mice and does not alter efficacy following Abeta immunotherapy.

Authors:  Pritam Das; Lisa A Smithson; Robert W Price; Vallie M Holloway; Yona Levites; Paramita Chakrabarty; Todd E Golde
Journal:  J Neuroinflammation       Date:  2006-07-26       Impact factor: 8.322
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.